Physician profile
Michael Mcandrew
NPI 1457462798
$2,783.87
in general payments reported to CMS, 2019-2025
14 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $384 · 2021: $413 · 2022: $524 · 2023: $464 · 2024: $546 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $944.00 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $423.46 | 2020-2024 | Trintellix |
| Abbvie INC. | $410.07 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $343.86 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $231.94 | 2021-2025 | Qelbree |
| Corium, LLC | $149.49 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $87.01 | 2024-2025 | Ingrezza |
| Tris Pharma INC | $80.56 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $39.47 | 2020-2021 | |
| Lundbeck LLC | $17.49 | 2020 | |
| W. L. Gore & Associates, INC. | $16.37 | 2023 | Gore Synecor Biomaterial |
| Vanda Pharmaceuticals INC. | $14.29 | 2019 | |
| Adlon Therapeutics L.P. | $13.92 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcandrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.